Log in to save to my catalogue

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapene...

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapene...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_353117

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

About this item

Full title

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Publisher

United States: Elsevier Ltd

Journal title

The Lancet infectious diseases, 2018-04, Vol.18 (4), p.391-400

Language

English

Formats

Publication information

Publisher

United States: Elsevier Ltd

More information

Scope and Contents

Contents

Colistin–carbapenem combinations are synergistic in vitro against carbapenem-resistant Gram-negative bacteria. We aimed to test whether combination therapy improves clinical outcomes for adults with infections caused by carbapenem-resistant or carbapenemase-producing Gram-negative bacteria.
A randomised controlled superiority trial was done in s...

Alternative Titles

Full title

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_DiVA_org_uu_353117

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_353117

Other Identifiers

ISSN

1473-3099,1474-4457

E-ISSN

1474-4457

DOI

10.1016/S1473-3099(18)30099-9

How to access this item